Pharmacological treatment for kleine-levin syndrome

Pharmacological treatment for kleine-levin syndrome

Author de Oliveira, Marcio M. Autor UNIFESP Google Scholar
Conti, Cristiane Autor UNIFESP Google Scholar
Prado, Gilmar F. Autor UNIFESP Google Scholar
Abstract Background This is an updated version of the original Cochrane review, published in 2009, Issue 2. Kleine-Levin syndrome (KLS) is a rare disorder that mainly affects adolescent men. It is characterised by recurrent episodes of hypersomnia, usually accompanied by hyperphagia, cognitive and mood disturbances, abnormal behaviour, such as hypersexuality, and signs of dysautonomia. In 1990, the diagnostic criteria for Kleine-Levin syndrome were modified in the International Classification of Sleep Disorders, where KLS was defined as a syndrome comprised of recurring episodes of undue sleepiness lasting some days, which may or may not be associated with hyperphagia and abnormal behaviour. According to the International Classification of Sleepiness Disorders, 3rd version (ICSD-3), revised in 2014, the Kleine-Levin syndrome is a disorder characterized by recurrent episodes of hypersomnia that last from two days to four weeks, with at least annual recurrence, and hyperphagia (rapid consumption of a large amount of food), usually with onset in early adolescence in males but occasionally in later life and in women. A monosymptomatic form of the disorder with hypersomnia only can occur without binge eating or hypersexuality. The cause of Kleine-Levin syndrome remains unknown, and several treatment strategies have been used. Some medications have been reported to provide benefit in the treatment of patients with KLS, but because of the rarity of the condition, no long-term follow-up therapies have yet been described. Objectives This review aimed to evaluate: 1. whether pharmacological treatment for Kleine Levin syndrome was effective and safe. 2. which drug or category of drugs was effective and safe. Search methods For the latest update, we searched the following sources: the Cochrane Epilepsy Group Specialized Register (7 April 2016)

the Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online CRSO (7 April 2016)

MEDLINE (1946 to April 2016)

LILACS (7 April 2016)

ClinicalTrials.gov (7 April 2016)

WHO International Clinical Trials Registry Platform ICTRP (7 April 2016)

reference lists of sleep medicine textbooks

review articles and reference lists of articles identified by the search strategies. Selection criteria All randomised controlled trials (RCTs) and quasi-randomised controlled trials looking at pharmacological interventions for Kleine-Levin syndrome were eligible. We had planned to include both parallel-group and cross-over studies. Data collection and analysis Two review authors (MMO and CC) had planned to extract the data reported in the original articles. Main results No studies met the inclusion criteria for this systematic review. Authors' conclusions Therapeutic trials of pharmacological treatment for Kleine-Levin syndrome with a double-blind, placebo-controlled design are needed.
Keywords Kleine-Levin Syndrome [drug Therapy]
Rare Diseases [drug Therapy]
HumansLithium
Carbamazepine
Encephalitis
Therapy
Variant
Sleep
Acid
Language English
Sponsor National Institute for Health Research (NIHR), UK, UK
National Institute for Health Research, via Cochrane Infrastructure funding
Date 2016
Published in Cochrane Database Of Systematic Reviews. Hoboken, n. 5, p. CD006685, 2016.
ISSN 1469-493X (Sherpa/Romeo, impact factor)
Publisher Wiley-blackwell
Extent CD006685
Origin http://dx.doi.org/10.1002/14651858.CD006685.pub4
Access rights Open access Open Access
Type Revisão
Web of Science ID WOS:000377961800041
URI http://repositorio.unifesp.br/handle/11600/49489

Show full item record




File

Name: WOS000377961800041.pdf
Size: 199.8Kb
Format: PDF
Description:
Open file

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account